基于个体化风险稳定性预测调整低危前列腺癌主动监测强度
该多中心前瞻性队列研究纳入850例低危前列腺癌主动监测患者,识别出预测活检升级的临床参数并建立模型,在533例外部验证队列中验证。模型预测4年未升级的AUC为0.70,低风险组阴性预测值达0.88至0.95,提示可据此调整个体化监测强度。
要点
- 最大阳性穿刺针百分比、既往阴性活检史、确诊时间、BMI、前列腺体积、诊断时PSA及PSA动力学可预测活检升级。
- 模型预测4年未升级的AUC在PASS队列和UCSF验证队列均为0.70。
- 风险最低25%和10%患者的阴性预测值分别为0.88和0.95,支持安全降低监测强度。
核心结论
- 低危前列腺癌患者后续活检升级风险存在异质性,可基于个体风险参数调整主动监测强度。
- 许多低危患者可能以显著降低的监测强度安全随访。
研究设计与样本
- Canary前列腺主动监测研究(PASS)为多中心前瞻性队列,2008年7月启动,中位随访4.1年,纳入850例低危前列腺癌患者。
- 外部验证在加州大学旧金山分校(UCSF)533例未入组PASS的主动监测患者中进行。
主要发现
- 预测4年未升级的AUC在PASS队列为0.70,UCSF验证队列为0.70。
- 风险最低25%组阴性预测值0.88(95%CI 0.83-0.94),最低10%组阴性预测值0.95(95%CI 0.89-1.00)。
临床怎么用
- 可依据最大阳性穿刺针百分比、既往阴性活检史、确诊时间、BMI、前列腺体积、诊断时PSA及PSA动力学等参数评估低危前列腺癌患者的活检升级风险。
- 对风险最低的患者可考虑降低主动监测强度,减少重复活检及相关焦虑、并发症和费用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Active surveillance is increasingly recognized as the preferred standard of care for men with low-risk prostate cancer. However, active surveillance requires repeated assessments, including prostate-specific antigen tests and biopsies that may increase anxiety, risk of complications, and cost. OBJECTIVE: To identify and validate clinical parameters that can identify men who can safely defer follow-up prostate cancer assessments. DESIGN, SETTING, AND PARTICIPANTS: The Canary Prostate Active Surveillance Study (PASS) is a multicenter, prospective active surveillance cohort study initiated in July 2008, with ongoing accrual and a median follow-up period of 4.1 years. Men with prostate cancer managed with active surveillance from 9 North American academic medical centers were enrolled. Blood tests and biopsies were conducted on a defined schedule for least 5 years after enrollment. Model validation was performed among men at the University of California, San Francisco (UCSF) who did not enroll in PASS. Men with Gleason grade group 1 prostate cancer diagnosed since 2003 and enrolled in PASS before 2017 with at least 1 confirmatory biopsy after diagnosis were included. A total of 850 men met these criteria and had adequate follow-up. For the UCSF validation study, 533 active surveillance patients meeting the same criteria were identified. Exclusion criteria were treatment within 6 months of diagnosis, diagnosis before 2003, Gleason grade score of at least 2 at diagnosis or first surveillance biopsy, no surveillance biopsy, or missing data. EXPOSURES: Active surveillance for prostate cancer. MAIN OUTCOMES AND MEASURES: Time from confirmatory biopsy to reclassification, defined as Gleason grade group 2 or higher on subsequent biopsy. RESULTS: A total of 850 men (median [interquartile range] age, 64 [58-68] years; 774 [91%] White) were included in the PASS cohort. A total of 533 men (median [interquartile range] age, 61 [57-65] years; 422 [79%] White) were included in the UCSF cohort. Parameters predictive of reclassification on multivariable analysis included maximum percent positive cores (hazard ratio [HR], 1.30 [95% CI, 1.09-1.56]; P = .004), history of any negative biopsy after diagnosis (1 vs 0: HR, 0.52 [95% CI, 0.38-0.71]; P < .001 and ≥2 vs 0: HR, 0.18 [95% CI, 0.08-0.4]; P < .001), time since diagnosis (HR, 1.62 [95% CI, 1.28-2.05]; P < .001), body mass index (HR, 1.08 [95% CI, 1.05-1.12]; P < .001), prostate size (HR, 0.40 [95% CI, 0.25-0.62]; P < .001), prostate-specific antigen at diagnosis (HR, 1.51 [95% CI, 1.15-1.98]; P = .003), and prostate-specific antigen kinetics (HR, 1.46 [95% CI, 1.23-1.73]; P < .001). For prediction of nonreclassification at 4 years, the area under the receiver operating curve was 0.70 for the PASS cohort and 0.70 for the UCSF validation cohort. This model achieved a negative predictive value of 0.88 (95% CI, 0.83-0.94) for those in the bottom 25th percentile of risk and of 0.95 (95% CI, 0.89-1.00) for those in the bottom 10th percentile. CONCLUSIONS AND RELEVANCE: In this study, among men with low-risk prostate cancer, heterogeneity prevailed in risk of subsequent disease reclassification. These findings suggest that active surveillance intensity can be modulated based on an individual's risk parameters and that many men may be safely monitored with a substantially less intensive surveillance regimen.
引用
- Cooperberg MR, Zheng Y, Faino AV, et al. Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. JAMA Oncol. 2020. PMID: 32852532. doi:10.1001/jamaoncol.2020.3187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。